PAC113

Phase 2Small molecule

PPacgen Biopharmaceuticals Corporation

PAC113 is one of 6 small molecule programs targeting Oral Candidiasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oral CandidiasisActive, not recruiting

Oral CandidiasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Oral Candidiasis

#DrugCompanyPhaseTrials

Lotrimin

Mycostatin

1 3

Inomax

MMallinckrodt

Approved

—4

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—5

PAC113

PPacgen Biopharmaceuticals Corporation

Phase 2

1 6

Frio Oral Rinse

BBiomedical Development Corporation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oral Candidiasis1 trial

Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis

Completed·PPacgen Biopharmaceuticals Corporation·Phase 2·NCT00659971·223 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PAC113. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PAC113 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PAC113. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pacgen Biopharmaceuticals Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPacgen Biopharmaceuticals Corporation

PAC113

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oral Candidiasis1 trial

References

Drug Info

Quick Facts

Related News